Prognostic Impact of Programmed Death Ligand-1 Expression in Advanced Endometrial Cancer

Institut de Cancérologie de Lorraine0 个研究点目标入组 80 人开始时间: 2016年1月最近更新: 2016年12月9日

适应症

试验速览

阶段: 不适用
状态: 已完成
发起方
入组人数: 80
主要终点: progression-free survival

研究概览研究设计入排标准结局指标研究者记录与标识符相似试验

研究概览

简要总结

The aim of this study was to assess the frequency of PD-L1 expression in stage III-IV ECs and to investigate its correlation impact with progression-free survival (PFS), and clinicopathological features including microsatellite instability and quantified stromal and intraepithelial tumor-infiltrating CD8+ lymphocytes (TILs)

研究设计

研究类型: Observational
观察模型: Case Only
时间视角: Retrospective

入排标准

年龄范围: 18 Years 至 —（Adult, Older Adult）
性别: Female
接受健康志愿者: 否

入选标准

•All patients consecutively enrolled from January 2004 to December 2014 treated for Endometrial cancer
•Stage III-IV endometrial cancer with available tissue blocks, including biopsies, hysterectomy specimens and resections of metastatic foci

排除标准

•A patient record captured outside the time frame from January 2004 to December 2014

结局指标

主要结局

progression-free survival

时间窗: 84 months

次要结局

未报告次要终点

研究者

发起方

Institut de Cancérologie de Lorraine

申办方类型

Other

责任方

Sponsor

相似试验

Unknown

不适用

The Predictive Role of Programmed Death Ligand 1 (PD-L1) and Neutrophil to Lymphocyte Ratio (NLR) in Non-Small Cell Lung Cancer (NSCLC)To Define an Easy and Feasible Panel Which May be Routinely Applied to Select Patients for Immunotherapy Avoiding More Complex and Expensive Methods

NCT03816657Fondazione Ricerca Traslazionale93

Unknown

不适用

PD-L1 Expression in Advanced OsteosarcomaProgressionSurvival

NCT03582527Peking University People's Hospital50

Unknown

不适用

Assessment of PD-1 and PD-L1Tissue Expression Levels in Lichen Planus Patients: A Case-Control StudyLichen Planus

NCT04892381Cairo University60

Unknown

2 期

Sintilimab in Combination With R-CHOP in Patients With Treatment-naive EBV-positive DLBCL, NOSEBV-Positive DLBCL, Nos

NCT04181489The First Affiliated Hospital with Nanjing Medical University55

Unknown

不适用

Effect of Chemotherapy on PD-L1 in NSCLCChemotherapyImmunotherapyPD-L1

NCT03701607Baodong Qin30